Figure 3.
Antitumour activity of 5-FU and XR5944 alone and in combination against the HT29 human colon carcinoma xenograft. (A) Tumour volume plotted as a percentage of that on day 0. (B) Animal body weight plotted as a percentage of that on day 0. All solutions were administered i.v. at 10 ml kg−1 using a q7dx3 dosing schedule and starting on day 0. 5-Fluorouracil was administered on days 0, 7, and 14, and XR5944 on days 2, 9, and 16. Data are expressed as means±s.e.m. n=7 except where indicated (where group size was changed partway through the study, this was due to tumour reaching maximum permitted diameter).